Published in Clin J Am Soc Nephrol on May 01, 2008
Update and critical appraisal of sevelamer in the management of chronic renal failure. Open Access J Urol (2010) 1.13
Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol (2012) 1.05
Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol (2011) 1.02
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol (2014) 1.01
Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence (2013) 0.99
Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther Adv Chronic Dis (2012) 0.84
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transplant (2010) 0.82
Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding. Ren Fail (2012) 0.81
Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients. Int J Nephrol Renovasc Dis (2014) 0.81
Phosphate Metabolism in CKD Stages 3-5: Dietary and Pharmacological Control. Int J Nephrol (2011) 0.80
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag (2008) 0.79
Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol (2009) 0.79
Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol (2017) 0.79
Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate. Perit Dial Int (2013) 0.78
Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol (2015) 0.78
A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis. Int J Nephrol Renovasc Dis (2014) 0.77
Phosphorus metabolism in chronic kidney disease. Hippokratia (2011) 0.76
Contemporary management of phosphorus retention in chronic kidney disease: a review. Clin Exp Nephrol (2015) 0.76
A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease. BMC Nephrol (2011) 0.75
Effects of the Use of Non-Calcium Phosphate Binders in the Control and Outcome of Vascular Calcifications: A Review of Clinical Trials on CKD Patients. Int J Nephrol (2011) 0.75
Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia (2011) 0.75
Model-Based Analysis of FGF23 Regulation in Chronic Kidney Disease. Gene Regul Syst Bio (2010) 0.75
Bicarbonate Balance and Prescription in ESRD. J Am Soc Nephrol (2016) 0.75
Phosphate binders in patients with chronic kidney disease. Aust Prescr (2017) 0.75
Effects of Sevelamer Hydrochloride on Uremic Toxins Serum Indoxyl Sulfate and P-Cresyl Sulfate in Hemodialysis Patients. J Clin Med Res (2017) 0.75
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 16.18
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol (2004) 6.59
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int (2005) 3.71
Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2005) 3.56
High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant (2007) 2.91
Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol (2005) 2.51
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis (1999) 2.07
Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.81
Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant (1999) 1.77
A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol (1999) 1.71
Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial (2005) 1.58
Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis (1997) 1.48
Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant (1998) 1.21
Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis (1992) 1.20
A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol (2007) 1.14
Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: a randomized placebo-control trial. J Am Soc Nephrol (2003) 1.09
The role of metabolic acidosis in the pathogenesis of renal osteodystrophy. Adv Ren Replace Ther (1995) 0.90
Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med (2009) 10.60
Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol (2002) 3.83
Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol (2008) 2.65
Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J (2008) 2.35
The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant (2005) 2.24
Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. Cancer (2011) 1.98
Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J (2005) 1.72
Fluid status in peritoneal dialysis patients: the European Body Composition Monitoring (EuroBCM) study cohort. PLoS One (2011) 1.67
A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis (2002) 1.65
Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant (2004) 1.61
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis (2006) 1.59
Body mass index has no effect on rate of progression of chronic kidney disease in non-diabetic subjects. Nephrol Dial Transplant (2012) 1.59
Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis (2011) 1.56
Prediction and assessment of responses to renal artery revascularization with dynamic contrast-enhanced magnetic resonance imaging: a pilot study. Am J Physiol Renal Physiol (2013) 1.46
Use of a first-line urine protein-to-creatinine ratio strip test on random urines to rule out proteinuria in patients with chronic kidney disease. Nephrol Dial Transplant (2008) 1.45
The clinical significance of hyperkalaemia-associated repolarization abnormalities in end-stage renal disease. Nephrol Dial Transplant (2012) 1.42
Reproducibility of a self-administered lifetime physical activity questionnaire among female college alumnae. Am J Epidemiol (2002) 1.41
Dialysis-dependent changes in ventricular repolarization. Pacing Clin Electrophysiol (2012) 1.39
[News from the Danish Society of Internal Medicine--the new DSIM ]. Ugeskr Laeger (2012) 1.39
Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol (2008) 1.25
Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.20
Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis (2010) 1.18
Measurement of single kidney function using dynamic contrast-enhanced MRI: comparison of two models in human subjects. J Magn Reson Imaging (2006) 1.17
Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Nephrol Dial Transplant (2009) 1.14
Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol (2011) 1.12
Pathophysiology of erectile dysfunction. J Sex Med (2005) 1.12
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One (2012) 1.10
Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease. Ann Clin Biochem (2009) 1.09
The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrol Dial Transplant (2010) 1.04
The effects of statins on the progression of atherosclerotic renovascular disease. Nephron Clin Pract (2007) 1.02
Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis (2004) 1.00
Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension (2002) 1.00
Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant (2011) 0.99
Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res (2004) 0.98
A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant (2009) 0.98
Is extracellular volume expansion of peritoneal dialysis patients associated with greater urine output? Blood Purif (2011) 0.97
BOLD imaging: a potential predictive biomarker of renal functional outcome following revascularization in atheromatous renovascular disease. Nephrol Dial Transplant (2011) 0.97
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant (2008) 0.96
Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. J Am Soc Nephrol (2002) 0.95
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum (2005) 0.95
Physiology of erectile function. J Sex Med (2004) 0.94
Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res (2009) 0.93
Validity and reproducibility of a physical activity questionnaire in women. Med Sci Sports Exerc (2002) 0.93
Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol (2010) 0.93
Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001. Circulation (2006) 0.92
The effect of racial origin on total body water volume in peritoneal dialysis patients. Clin J Am Soc Nephrol (2011) 0.91
Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis (2009) 0.90
Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization. J Biol Chem (2011) 0.90
Effects of renal volume and single-kidney glomerular filtration rate on renal functional outcome in atherosclerotic renal artery stenosis. Nephrol Dial Transplant (2009) 0.88
Factors associated with vascular stiffness: cross-sectional analysis from the Chronic Renal Insufficiency Standards Implementation Study. Nephron Clin Pract (2009) 0.86
Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol (2005) 0.86
Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J (2013) 0.86
A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant (2005) 0.85
Anuric acute renal failure and pulmonary oedema: a case for urgent action. Int J Cardiol (2007) 0.85
Systemic lupus erythematosus, eosinophilic vasculitis and acalculous cholecystitis. Nephrol Dial Transplant (2005) 0.85
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis (2009) 0.85
Dilemmas in the management of renal artery stenosis. Br Med Bull (2005) 0.84
A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. Nephrol Dial Transplant (2013) 0.84
Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease. J Ren Care (2009) 0.83
Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging (2009) 0.83
Progression of cardiac dysfunction in patients with atherosclerotic renovascular disease. QJM (2009) 0.83
Vascular calcification: lessons from scientific models. J Ren Care (2009) 0.83
Improved left ventricular filling following bilateral renal artery stenting. Int J Cardiol (2009) 0.83
Atherosclerotic renovascular disease and the heart. J Ren Care (2010) 0.83
Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr (2008) 0.83
Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus. J Nephrol (2012) 0.82
Diagnostic accuracy of the urinary albumin: creatinine ratio determined by the CLINITEK Microalbumin and DCA 2000+ for the rule-out of albuminuria in chronic kidney disease. Clin Chim Acta (2008) 0.82
The heart in atherosclerotic renovascular disease. Front Biosci (Elite Ed) (2012) 0.82
Small bowel angiodysplasia in a patient on haemodialysis: difficulties in diagnosis and management. BMJ Case Rep (2009) 0.81
Current management of atherosclerotic renovascular disease--what have we learned from ASTRAL? Nephron Clin Pract (2010) 0.81
Therapeutic implications of coexisting severe pulmonary hemorrhage and pulmonary emboli in a case of Wegener granulomatosis. Am J Kidney Dis (2009) 0.81
Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study. Eur Urol (2003) 0.81
Challenges in diagnosing acute pancreatitis in renal transplant patients. Clin Transplant (2009) 0.80
Extreme Elevations in Blood Pressure and All-Cause Mortality in a Referred CKD Population: Results from the CRISIS Study. Int J Hypertens (2013) 0.80
Epidemiology and investigation of acute abdominal presentations in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2007) 0.80
Where now in the management of renal artery stenosis? Implications of the ASTRAL and CORAL trials. Curr Opin Nephrol Hypertens (2014) 0.80
Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study. Nephrol Dial Transplant (2010) 0.80
Parathyroid hormone-related peptide plasma concentrations in patients on hemodialysis. Scand J Clin Lab Invest (2014) 0.79
Predictive value of myocardial and coronary imaging in the long-term outcome of potential renal transplant recipients. Int J Cardiol (2009) 0.79
Novel Approach to Cardiovascular Outcome Prediction in Haemodialysis Patients. Am J Nephrol (2016) 0.79
Prostate cancer-specific survival differences in patients treated by radical prostatectomy versus curative radiotherapy. Can Urol Assoc J (2013) 0.78
Determinants of renal functional outcome in lupus nephritis: a single centre retrospective study. QJM (2008) 0.78
The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Care (2010) 0.78
Sudden cardiac death in haemodialysis patients: preventative options. Nephrology (Carlton) (2014) 0.78
The prognostic value of electrocardiographic estimation of left ventricular hypertrophy in dialysis patients. Ann Noninvasive Electrocardiol (2012) 0.78
Vascular calcification in chronic kidney disease: a clinical review. J Ren Care (2009) 0.77
Effect of CD40 and sCD40L on renal function and survival in patients with renal artery stenosis. Hypertension (2013) 0.77
Mechanical thrombectomy of occluded hemodialysis native fistulas and grafts using a hydrodynamic thrombectomy catheter: preliminary experience. Cardiovasc Intervent Radiol (2005) 0.77
Reverse cardiac remodelling and renal functional improvement following bilateral renal artery stenting for flash pulmonary oedema. Nephrol Dial Transplant (2012) 0.77
Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. Kidney Blood Press Res (2009) 0.76
Could urological questionnaires completely replace physiological testing? BJU Int (2005) 0.76
Indirect measurement of bioavailable testosterone with the Bayer Immuno 1 system. Clin Chem (2002) 0.76
Renal revascularization for heart failure in patients with atherosclerotic renovascular disease. Nephrol Dial Transplant (2010) 0.76
Echocardiographic abnormalities in dialysis patients with normal ejection fraction. Nephrol Dial Transplant (2012) 0.75
Meta-analysis of lipid-lowering therapy in maintenance dialysis patients. Nephron Clin Pract (2014) 0.75